At a Glance

Betteromics is revolutionizing life sciences and healthcare data synthesis through an AI-driven multi-omics cloud platform, automating workflow across collection, abstraction, and analysis, with rigorous accuracy and traceability, unlocking immense potential across diagnostic and therapeutic developments.

Redwood City, CA
Investment Timeline
Founder Discussion
February 21, 2024
Commitment Deadline
March 8, 2024
Funding Due
March 14, 2024

Introduction to Omics

Betteromics is the first-to-market AI cloud-based, multi-omics data and analysis platform for the life sciences and biotechnology industry. We are in an unprecedented time with the rapid development of technologies such as high-throughput sequencing that opened the door for omics by systematically interrogating a cellular system. The ever-growing types of molecules and regulatory mechanisms that are being discovered have transformed our understanding of cellular machinery, enabling several breakthroughs.

These advancements have resulted in an explosion of data generation, providing researchers and scientists with incredible resources to better understand human biology and how different diseases affect it. See the above introductory video that highlights the unprecedented change in the industry that Betteromics is advancing.


  • AI-Powered Omics Platform: Betteromics has developed an AI-native, cloud-based omics data platform capable of servicing life sciences customers from pre-clinical target and drug discovery to clinical stage development, providing rapid development capabilities.

  • Omics Evolution: The study of the human cell, in general referred to as ‘omics,’ includes the combination of genomics (DNA), transcriptomics (RNA), proteomics (proteins) and metabolomics (metabolites). Technological advances in computational biology, sequencing, and testing have resulted in massive amounts of data that requires multi-omics analysis to unlock new therapeutics and diagnostics, but requires a platform capable of encompassing these distinct fields.

  • Timing & Demand are Aligned: AI and software tools have already begun being adopted by the biotech industry, with macroeconomic shifts from ‘build’ to ‘buy’ taking place throughout the market. Multi-omics analysis historically has been a manual and highly human-driven process, requiring enormous investments in time and expenses to develop. Technological advancements over the past few years have created the opportunity for a platform like Betteromics’ to automate and streamline workflows across different sectors with a compelling value proposition. Some of their customers include Twist Bioscience, Mission Bio, Montai Health and Elegen Bio.

  • Exploding Market Opportunity: Growth forecasts for the big data analytics market in healthcare are projected to reach over $45 billion in 2026. In addition, the IT budget at large pharma companies like Pfizer and Moderna is close to $1 billion per potential customer, creating a viable, serviceable, and sticky market for Betteromics.

  • Top Industry Experts: Betteromics is led by a veteran executive team with deep industry and technical experience from Google, GRAIL, and Verily Life Sciences. Founder and CEO Angela Lai is a technology executive and founder with 30 years of experience building computing infrastructure and ML platforms at global scale at Silicon Graphics, Google, and GRAIL, where she served as Head of Clinical Technology and CTO prior to founding Betteromics.
  • Strong Strategic Investor Group: The current Series A round was led by Triatomic Capital, founded by Jeff Huber (Founding CEO, GRAIL, an advanced cancer-screening company acquired by Illumina) and Sofinnova Partners (leading European venture capital firm in life sciences), with participation from and Shakti VC, Decheng Capital and Unusual Ventures, among others.

Investment Opportunity

Plum Alley is excited to announce a new Series A investment opportunity in Betteromics. The Company has raised $20 million in Series A funding, which closed in December, 2023. Due to an oversubscription in investor interest, Betteromics agreed to extend the round for an additional $5 million for select investors. The round was co-led by Triatomic Capital and Sofinnova Partners, with participation from Shakti VC, Decheng Capital and Unusual Ventures. While the Company closed their round with prominent investors and luminaries in the industry, Plum Alley's relationship over the last year with the lead investor and founder allowed us to secure an allocation in the Company.


Virtual Founder Discussion

Wednesday, February 21st

12:30pm ET // 9:30am PT

RSVP to Google Calendar Invite

Call Details Available Here

Final Investment Commitments Due

Thursday, February 29th

We will take commitments on a rolling basis. Please submit final commitments here.

Funding & Documents Due

Thursday, March 7th

At the end of the commitment period, you will receive details regarding closing documentation and wiring instructions via Carta.

The Company's confidential financing documents and diligence materials are available for review in DropBox. Request access here. All documents are confidential and not for further distribution. If you have specific questions or are interested in investing in Betteromics, please contact us and submit your investment total here.

Overview: Why Betteromics Was Founded

A Revolutionary Advancement

Betteromics is on the forefront of using 'omics' data and AI to unlock the potential of a radically different and better therapeutic discovery and healthcare system. In biology, the word 'omics' refers to the sum of constituents within a cell and the overarching aim of identifying, describing, and quantifying the biomolecules and molecular processes that contribute to the form and function of cells and tissues. Omics is a rapidly evolving and multi-disciplinary emerging field that gives us the way to understand and view biology from an all-encompassing perspective that was previously unthinkable. With high-throughput methodologies, we can see into cells at multiple levels, allowing for unprecedented and accelerated new discoveries in disease and treatment.

‘Omics’ Overview

Omics works by probing and analyzing large amounts of data on the structure and function of the entire machinery inherent in a given biological system at a particular level. There are four core areas of omics, which when combined present powerful new discoveries. The four are genomics (DNA), transcriptomics (RNA), proteomics (proteins) and metabolomics (metabolites). Since efforts began in mapping and sequencing the human genome in 1990, revolutionary technologies have emerged, facilitating the collection of a wide range of molecular measurements within a tissue or cell with unprecedented levels of insights and data. This multidisciplinary approach to biological and medical research and discovery has transformed the biotech industry, resulting in immense advancements in high-throughput testing and screening technologies.

Over the past two decades, the adoption of advanced equipment and computational techniques has resulted in an explosion in scientific data across the field of ‘omics’. For example, according to the National Human Genome Research Institute, the cost of sequencing the human genome has dropped from $450M in global costs for the initial human genome sequence over a decade (1990-2003) to less than $1,000.

This rapid evolution has led scientific research teams to now incorporate statisticians, computational biologists, software engineers and data scientists just to make sense of the massive amount of data now utilized to advance medicine across therapeutics, diagnostics, and predictive medicine. However, the pace of evolution for the technology empowering these disparate fields to collaborate have not kept up, with niche software programs for specific instruments, incongruous data formats, and manual processes presenting significant roadblocks to workflows across data capture, processing, and analysis. These data silos and point solutions cause discovery and development processes to take weeks or months to complete, with many avenues for error causing even further delays. And, eventually ineffective drug discoveries.

Explosion in Complexity in Science and Technology

Betteromics was built to serve as the omics AI cloud to connect data and people, enabling researchers to automate the flow of data between collection, abstraction, and analysis, while maintaining rigorous accuracy and traceability. The advent of technology tools that enable rapid, at-scale, and high quality data abstraction are recent developments in the AI field, and Betteromics is perfectly timed to maximize this utility in the biotech space. The Company’s initial deployment of these tools has resulted in significant reductions to the most capital intensive aspect of platform creation and maintenance to a fraction of what it would have been even a year ago, resulting in enormous opportunities to scale with customers of any size. Betteromics solves the problem of omics data that currently is in incongruous formats and managed through manual processes causing significant roadblocks to workflows for therapeutic discoveries.

Market Opportunity & Customer Traction

Market Components

The approach to discovering drugs via multi-omics molecular modeling can be more precise than even high-throughput drug screening methods used today, and from a financial perspective can dramatically speed up the development of target discovery on disease pathways to drug development. The faster these processes can be completed, the faster these novel drugs can make it to market and begin generating revenue.

The primary target market for Betteromics’ AI cloud-based solution is primarily preclinical drug discovery companies seeking to generate new IP from multi-omics data. The Company provides these customers end-to-end ingestion, processing, and analysis of complex data in a comprehensive platform capable of yielding insights faster and more accurately than disparate legacy systems.

Betteromics is capitalizing on the clinical-stage discovery companies seeking to validate novel therapeutics, particularly with phenotypic outcomes that require similar integrated solutions but with added emphasis on patient identification and regulatory compliance.

Market Size

Pharmaceutical, biotech and research companies only are turning to external reliable platforms and services to build and grow their research capabilities. According to Grandview Research, the total IT outlays for drug discovery by preclinical companies-only is ~$3.3 billion. The IT budget at large pharma companies like Pfizer and Moderna is close to $1 billion per customer. The exponential growth in the “multi omics” data and systems is creating a rapidly growing new market segment. Companies like Grail, Twist, MissionBio, and Montai Health are examples of a growing market of suppliers for everything from genomic to proteomic information. Collectively these four companies alone make up nearly $10 billion in market cap valuation of the new and growing market.

Customer Traction

Betteromics has created a market-oriented solution for the biotech and research pharmaceutical industry and grew to $1.3 million in ARR in 2023, with total revenues of $2.03 million. They also have a strong near-term and long term customer pipeline providing continued growth opportunities.

February 2024 Customer Pipeline

Recent customer acquisitions for Betteromics includes Montai Health and Elegen. They also recently signed Twist Bioscience (NASDAQ:TWST), a public company with a $2.1 billion market cap specializing in manufacturing synthetic DNA for clinical research, among others. Since launching commercial sales efforts, Betteromics has converted notable customers across its sales pipeline, some of whom include Harbinger Health, Pfizer ClinOps, Cure 51, Mission Bio, Cellares, and Manifold Bio.

Leadership Team & Advisors

Angela Lai (CEO, Co-Founder)

Technology executive with nearly 3 decades of experience building complex computing infrastructure and machine-learning platforms at a global scale, including for regulated industries such as healthcare and financial payments. Formerly CTO of GRAIL (sold to Illumina for $7 billion, and Google Engineering VP in Ads, Payments, Search and Knowledge Graph. With deep product, business strategy and engineering expertise, Angela has recruited, built, and retained strong and diverse product and engineering teams.

Jack Menzel (Chief Product Officer)

Data-driven product executive whose previous experience includes 15+ years at Google (VP, Product Management) building and leading teams in Ads, YouTube, Maps and Search, where he was the founding member of Knowledge Graph product.

Chetan Patel (Chief Technology Officer, Co-Founder)

Technology executive bringing 25+ years of hands-on software industry experience including founding 3 startups along with executive roles at Google (Senior Director) and Grail (VP, Engineering). He has a unique experience in building massive high traffic low latency infrastructures.

David Norman (Chief Information Security Officer)

Experienced founder with two successful software platform companies alongside two decades of tech experience. Former Senior Software Engineer experience at Google for 8 years, and Applications Engineer at Wells Fargo for 4 years. Lead engineer for information security across inter-system and inter-application teams, with large scale, distributed environment experience.

Szymon Perkowski (Head of Quality)

Executive with 15+ years of experience in product development, quality, regulatory, security, privacy, and program management with Genentech, Verily, and Google. Certified Quality Auditor, Regulatory Affairs Certification, Agile Certified Practitioner. Record of results includes successfully launching fully integrated quality and information security management systems.

Top Industry Experts with Unparalleled Expertise

This Series A investment opportunity attracted investors at the helm of this massive evolution of data to solve for difficult diseases. Jeff Huber, the lead Seed round investor and co-lead for the Series A, has extraordinary credentials as the former CEO and founder of GRAIL, a pioneering technology company focused on early detection of multiple deadly cancers. GRAIL sold to Illumina for approximately $7 billion. Jeff also co-founded Google's life sciences efforts at X Development (formerly GoogleX), and led development and scaling for Google Maps and Google Ads, overseeing 50x growth in revenues at Google to $50 billion. He is now the co-founder of Triatomic Capital, a venture capital firm investing in 'century-defining' technologies. Angela Lai, the founder of Betteromics and the former CTO at GRAIL, worked closely with Jeff Huber. Additionally, Sofinnova Partners, a deep-pocketed healthcare investment firm with $3B in AUM and relevant expertise is co-leading the round.

Joining Jeff Huber on the advisory board is Jennifer Cook, an experienced board member with decades of experience in biotech. Most recently, she was the Chief Executive Officer of GRAIL, a healthcare company focused on the early detection of cancer. Previously, Jennifer was at Roche Pharmaceuticals / Genentech, where she held a number of senior management positions, covering the full lifecycle of pharmaceutical product development and commercialization, including Head of Europe for Roche leading 5,500 employees across 28 countries in the region. In 2016, Jennifer was recognized for her contributions to the healthcare industry and her inspirational leadership when she was named Woman of the Year by the Healthcare Businesswomen’s Association.

In addition, Betteromics is supported by Mark Lee, who has been at the forefront of personalized healthcare for 15+ years, in leadership roles at preeminent companies in this space. Most recently, he was SVP and Global Head for Personalized Healthcare, Product Development at Genentech/Roche, spearheading transformation of drug development and care delivery through data-at-scale and technology. Previously, Mark was on the founding team for GRAIL, where he built one of the largest clinical research programs for early cancer detection.  Mark’s previous roles also include Lead for Oncology Clinical Sciences at Google[x] Life Sciences, Chief Medical Officer at Boreal Genomics, and Vice President of Oncology Development at Genomic Health, where he led the successful development and validation of the Oncotype DX tests for Colon and Prostate.

Technology & Product

Platform SaaS Offering

Betteromics offers an end-to-end omics data platform that supports the full lifecycle of data science in biotech across markets with the following key components:

1. Data Collection

The platform facilitates collection and storage of multi-omics lifesciences data. Users may pull from structured sources (ex. lab devices, assay readouts, EMRs, etc) and unstructured sources (ex. clinical notes, imaging, pathology samples, etc) using comprehensive ingestion, natural language processing, and abstraction methods. Input components are also dynamic, so that data capture is not just a static snapshot, but rather is set up to evolve as data itself changes over time.

2. Transformation and Processing

Collected data is automated in a pipeline that enables semantic and syntactic normalization (a necessary step to making data actionable). Current market solutions require clients to implement and maintain computationally intensive, error prone, and fragile processing pipelines in order to conduct these transformations. Betteromics removes these costs by implementing configurable recipes that clients use to create their desired output. In addition, by providing full lifecycle processing, Betteromics enables complete lineage and traceability by default - an auditability and regulatory requirement especially for clinical data analysis.

3. Data Interoperability

Betteromics includes a Knowledge Graph that connects all applicable life sciences ontologies and vocabularies. This Knowledge Graph directly enables annotation, semantic interoperation, and analysis, improving customers’ ability to derive and validate new IP in rapid fashion, and makes interoperability with other internal and external data sources negligible from a cost perspective.

4. Searchability and Analysis

Betteromics houses customer data in a scalable, graph-enabled knowledge store. This enables novel analysis and search methods compared to existing market offerings.

5. Assisted Machine Learning

With all data connected back to the source observation, Betteromics facilitates current machine learning methods to augment manual task review in order to create source and training data. This allows the Betteromics system to scale human domain expertise, which is a major contributor to the Company’s ability to invert the standard cost curve seen in first generation data platforms.

AI Network Benefits

Betteromics is an AI-native platform, and as such, each incremental customer use-case accumulates knowledge and capabilities into the platform. Every omic dataset that is incorporated to the product increases the Company’s ability to service that domain, and each insight-generating query increases the AI model’s ability to predict and provide future IP generation and validation.

This is a network effect in line with LLMs that are now becoming commercially viable. Current and legacy competitors limit networked value to transactions between customers, while the Betteromics model goes a step further by embedding that value directly into the capabilities of the platform, such that customers who aren't even connected benefit directly from more powerful insights and reduced costs afforded by every other customer.


Technological advancements over the past few years have created the opportunity for a platform like Betteromics’ to automate and streamline workflows across different sectors with a compelling and affordable value proposition towards supporting better, faster, and more affordable and accessible therapeutic discoveries for patients. The expanding knowledge base of diseases and human biology allows Betteromics technology to support and develop more efficient and effective drugs that are accessible and affordable in a timely manner.